TY  - THES
A1  - Liang, Chunguang
T1  - Tools for functional genomics applied to Staphylococci, Listeriae, Vaccinia virus and other organisms
N2  - Genome sequence analysis A combination of genome analysis application has been established here during this project. This offers an efficient platform to interactively compare similar genome regions and reveal loci differences. The genes and operons can be rapidly analyzed and local collinear blocks (LCBs) categorized according to their function. The features of interests are parsed, recognized, and clustered into reports. Phylogenetic relationships can be readily examined such as the evolution of critical factors or a certain highly-conserved region. The resulting platform-independent software packages (GENOVA and inGeno), have been proven to be efficient and easy to handle in a number of projects. The capabilities of the software allowed the investigation of virulence factors, e.g., rsbU, strains’ biological design, and in particular pathogenicity feature storage and management. We have successfully investigated the genomes of Staphylococcus aureus strains (COL, N315, 8325, RN1HG, Newman), Listeria spp. (welshimeri, innocua and monocytogenes), E.coli strains (O157:H7 and MG1655) and Vaccinia strains (WR, Copenhagen, Lister, LIVP, GLV-1h68 and parental strains). Metabolic network analysis Our YANAsquare package offers a workbench to rapidly establish the metabolic network of such as Staphylococcous aureus bacteria in genome-scale size as well as metabolic networks of interest such as the murine phagosome lipid signalling network. YANAsquare recruits reactions from online databases using an integrated KEGG browser. This reduces the efforts in building large metabolic networks. The involved calculation routines (METATOOL-derived wrapper or native Java implementation) readily obtain all possible flux modes (EM/EP) for metabolite fluxes within the network. Advanced layout algorithms visualize the topological structure of the network. In addition, the generated structure can be dynamically modified in the graphic interface. The generated network as well as the manipulated layout can be validated and stored (XML file: scheme of SBML level-2). This format can be further parsed and analyzed by other systems biology software, such as CellDesigner. Moreover, the integrated robustness-evaluation routine is able to examine the synthesis rates affected by each single mutation throughout the whole network. We have successfully applied the method to simulate single and multiple gene knockouts, and the affected fluxes are comprehensively revealed. Recently we applied the method to proteomic data and extra-cellular metabolite data of Staphylococci, the physiological changes regarding the flux distribution are studied. Calculations at different time points, including different conditions such as hypoxia or stress, show a good fit to experimental data. Moreover, using the proteomic data (enzyme amounts) calculated from 2D-Gel-EP experiments our study provides a way to compare the fluxome and the enzyme expression. Oncolytic vaccinia virus (VACV) We investigated the genetic differences between the de novo sequence of the recombinant oncolytic GLV-1h68 and other related VACVs, including function predictions for all found genome differences. Our phylogenetic analysis indicates that GLV-1h68 is closest to Lister strains but has lost several ORFs present in its parental LIVP strain, including genes encoding CrmE and a viral Golgi anti-apoptotic protein, v-GAAP. Functions of viral genes were either strain-specific, tissue-specific or host-specific comparing viral genes in the Lister, WR and COP strains. This helps to rationally design more optimized oncolytic virus strains to benefit cancer therapy in human patients. Identified differences from the comparison in open reading frames (ORFs) include genes for host-range selection, virulence and immune modulation proteins, e.g. ankyrin-like proteins, serine proteinase inhibitor SPI-2/CrmA, tumor necrosis factor (TNF) receptor homolog CrmC, semaphorin-like and interleukin-1 receptor homolog proteins. The contribution of foreign gene expression cassettes in the therapeutic and oncolytic virus GLV-1h68 was studied, including the F14.5L, J2R and A56R loci. The contribution of F14.5L inactivation to the reduced virulence is demonstrated by comparing the virulence data of GLV-1h68 with its F14.5L-null and revertant viruses. The comparison suggests that insertion of a foreign gene expression cassette in a nonessential locus in the viral genome is a practical way to attenuate VACVs, especially if the nonessential locus itself contains a virulence gene. This reduces the virulence of the virus without compromising too much the replication competency of the virus, the key to its oncolytic activity. The reduced pathogenicity of GLV-1h68 was confirmed by our experimental collaboration partners in male mice bearing C6 rat glioma and in immunocompetent mice bearing B16-F10 murine melanoma. In conclusion, bioinformatics and experimental data show that GLV-1h68 is a promising engineered VACV variant for anticancer therapy with tumor-specific replication, reduced pathogenicity and benign tissue tropism.
N2  - Genom Sequenz Analyse Im Zuge der vorliegenden Doktorarbeit wurden verschiedene Programme zur Genomanalyse kombiniert, um eine effiziente Plattform zum interaktiven Vergleich lokaler Ähnlichkeiten bzw. Unterschiede in Genomen bereitzustellen. Damit können Gene und Operons schnell untersucht und “local collinear blocks” entsprechend ihrer Funktion kategorisiert werden. Phylogenetische Beziehungen, wie beispielsweise die Evolution spezifischer Elemente oder stark konservierter Regionen können leicht überprüft werden. Die hierfür entwickelte plattformunabhängige Software (GENOVA und inGeno) hat sich in mehreren Projekten als effizient und leicht handhabbar bewährt. Die Programme erlauben die Untersuchung von Virulenzfaktoren auf Sequenz- oder Annotationsebene. Während der vorliegenden Doktorarbeit konnten so die Genome von verschiedenen Staphylococcus aureus, Listeria spp., Escherichia coli und Vaccinia Stämmen untersucht werden. Metabolische Netzwerk Analyse Unser “YANAsquare” Programmpaket bietet eine Oberfläche um schnell metabolische Netzwerke vom genomweiten Anzatz bis hinunter zum Einzelnetzwerk zu analysieren. Dafür greift YANA mit Hilfe des integrierten KEGG-Browsers auf Onlinedatenbanken zu, um die notwendigen Informationen zum metabolischen Reaktionsweg bereitzustellen und reduziert so maßgeblich den Arbeitsaufwand beim Beschreiben von Netzwerke. Die implementierten Methoden zur Berechnung (METATOOL, eigene Implementation in Java) des Netzwerkes liefern exakt alle die möglichen Elementarmoden (EM/EP) für die Metabolite zurück. Durch den Einsatz von fortgeschrittenen Layout Algorithmen wird anschliessend die Darstellung der Netzwerktopologie möglich. Außerdem kann in der grafischen Darstellung das generierte Netzwerklayout dynamisch verändert werden. Das Speichern der Daten erfolgt im XML (SBML level-2) Format und erlaubt so die Weiterverwendung in anderen systembiologischen Programmen, wie dem “CellDesigner”. Mit Hilfe einer gen-Knockout Simulations Methode kann der Einfluss von einzelnen Mutationen im gesamten Netzwerk auf die Syntheseraten untersucht werden. Wir konnten mit dieser Methode Einzel- sowie Mehrfachgenknockouts und deren Effekte auf die Elementarmoden analysieren. Die Methode wurde ebenfalls auf Proteomdaten und extrazelluläre Metabolite von Staphylokokken angewandt, um Änderungen bezüglich der Flussverteilung zu untersuchen. Die Simulationen zu verschieden Zeitpunkten und unter verschiedenen Stessbedingungen zeigen große Übereinstimmung mit experimentell erhobenen Daten. Onkolytischer Vaccinia Virus (VACV) Wir haben die genetischen Unterschiede zwischen der de novo Sequenz des rekombinanten onkolytischen Virus GLV-1h68 und anderen VACVs untersucht und gefundene Unterschiede funktionell charakterisiert. Die phylogenetische Analyse zeigt das GLV-1h68 mit dem Lister Stamm am nächsten verwandt ist. Auffällig ist dabei der Verlust von einigen open reading frames (ORFs), die noch im Eltern LIVP Stamm vorhanden sind (CrmE, v-GAAP). Beim Vergleich der Funktion viraler Gene aus Lister, WR und COP Stämmen treten stamm-, gewebe- und wirtsspezifische Gene auf. Diese Tatsache ermöglicht die Optimierung der onkolytischen Virusstämme für den Einsatz bei humanen Krebstherapien. Die beim Vergleich identifizierten Unterschiede zwischen den ORFs enthalten Gene für die Wirtsselektion, Virulenz und immunmodulierende Proteine (Ankyrin ähnliche Proteine, Serine-Proteinasen Inhibitor SPI-2/CrmA, Tumor Nekrose Faktor (TNF) Rezeptorhomolog CrmC, semaphorinähnliche und Interleukin-1 rezeptorhomologe Proteine). An den Loki F14.5L, J2R und A56R des GLV-1h68 Virus wurden die Vorteile der eingesetzten fremden Genexpressionskassetten untersucht. So zeigt GLV-1h68 mit F14.5L-Inaktivierung gegenüber der F14.5L-Revertanten Viren eine reduzierte Virulenz. Das erlaubt die Schlussfolgerung, dass die Insertion von fremden Genexpressionskassetten in nicht-essentielle Loki zur Verminderung der Virulenz von VACVs führt, besonders, wenn der nicht-essentielle Lokus selbst ein Virulenzgen enthält. Das Replikationsvermögen, welches ausschlaggebend für die onkolytische Aktivität des Virus ist, wird trotz der verminderten Virulenz nicht eingeschränkt. Die reduzierte Pathogenität des GLV-1h68 Virus wurde durch experimentelle Daten unserer Kollaborationspartner in männlichen Mäusen mit Ratten C6 Gliom und in immunokompetenten Mäusen mit B16-F10 Mausmelanom nachgewiesen. Zusammenfassend zeigen experimentelle und bioinformatisch gewonnene Daten, dass GLV-1h68 eine vielversprechende VACV Variante für die Krebstherapie mit tumorspezifischer Replikation, verringerter Pathogenität und hoher Gewebsspezifität ist.
KW  - Genanalyse
KW  - Bioinformatik
KW  - Systembiologie
KW  - bacterial
KW  - virulence
KW  - systems biologie
KW  - genomic
KW  - algorithm
KW  - metabolic
KW  - network
KW  - pathway
KW  - flux
KW  - Bacterial
KW  - genomics
KW  - algorithm
KW  - tool
KW  - metabolic
Y1  - 2009
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-48051
ER  - 
TY  - JOUR
A1  - Zanucco, Emanuele
A1  - Götz, Rudolf
A1  - Potapenko, Tamara
A1  - Carraretto, Irene
A1  - Ceteci, Semra
A1  - Ceteci, Fatih
A1  - Seeger, Werner
A1  - Savai, Rajkumar
A1  - Rapp, Ulf R.
T1  - Expression of B-RAF V600E in Type II Pneumocytes Causes Abnormalities in Alveolar Formation, Airspace Enlargement and Tumor Formation in Mice
JF  - PLOS ONE
N2  - Growth factor induced signaling cascades are key regulatory elements in tissue development, maintenance and regeneration. Perturbations of these cascades have severe consequences, leading to developmental disorders and neoplastic diseases. As a major function in signal transduction, activating mutations in RAF family kinases are the cause of human tumorigenesis, where B-RAF V600E has been identified as the prevalent mutant. In order to address the oncogenic function of B-RAF V600E, we have generated transgenic mice expressing the activated oncogene specifically in lung alveolar epithelial type II cells. Constitutive expression of B-RAF V600E caused abnormalities in alveolar epithelium formation that led to airspace enlargements. These lung lesions showed signs of tissue remodeling and were often associated with chronic inflammation and low incidence of lung tumors. The inflammatory cell infiltration did not precede the formation of the lung lesions but was rather accompanied with late tumor development. These data support a model where the continuous regenerative process initiated by oncogenic B-RAF-driven alveolar disruption provides a tumor-promoting environment associated with chronic inflammation.
KW  - obstructive pulmonary-disease
KW  - lung-cancer
KW  - somatic mutations
KW  - epithelial-cells
KW  - mouse models
KW  - protein
KW  - kinase
KW  - inflammation
KW  - activation
KW  - pathway
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137061
VL  - 6
IS  - 12
ER  - 
TY  - JOUR
A1  - Zirkel, J.
A1  - Cecil, A.
A1  - Schäfer, F.
A1  - Rahlfs, S.
A1  - Ouedraogo, A.
A1  - Xiao, K.
A1  - Sawadogo, S.
A1  - Coulibaly, B.
A1  - Becker, K.
A1  - Dandekar, T.
T1  - Analyzing Thiol-Dependent Redox Networks in the Presence of Methylene Blue and Other Antimalarial Agents with RT-PCR-Supported in silico Modeling
JF  - Bioinformatics and Biology Insights
N2  - BACKGROUND: In the face of growing resistance in malaria parasites to drugs, pharmacological combination therapies are important. There is accumulating evidence that methylene blue (MB) is an effective drug against malaria. Here we explore the biological effects of both MB alone and in combination therapy using modeling and experimental data.
RESULTS: We built a model of the central metabolic pathways in P. falciparum. Metabolic flux modes and their changes under MB were calculated by integrating experimental data (RT-PCR data on mRNAs for redox enzymes) as constraints and results from the YANA software package for metabolic pathway calculations. Several different lines of MB attack on Plasmodium redox defense were identified by analysis of the network effects. Next, chloroquine resistance based on pfmdr/and pfcrt transporters, as well as pyrimethamine/sulfadoxine resistance (by mutations in DHF/DHPS), were modeled in silico. Further modeling shows that MB has a favorable synergism on antimalarial network effects with these commonly used antimalarial drugs.
CONCLUSIONS: Theoretical and experimental results support that methylene blue should, because of its resistance-breaking potential, be further tested as a key component in drug combination therapy efforts in holoendemic areas.
KW  - methylene blue
KW  - malaria
KW  - elementary mode analysis
KW  - drug
KW  - resistance
KW  - combination therapy
KW  - pathway
KW  - metabolic flux
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123751
N1  - This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
VL  - 6
ER  - 
TY  - JOUR
A1  - Jain, Preetesh
A1  - Javdan, Mohammad
A1  - Feger, Franziska K.
A1  - Chiu, Pui Yan
A1  - Sison, Cristina
A1  - Damle, Rajendra N.
A1  - Bhuiya, Tawfiqul A.
A1  - Sen, Filiz
A1  - Abruzzo, Lynne V.
A1  - Burger, Jan A.
A1  - Rosenwald, Andreas
A1  - Allen, Steven L.
A1  - Kolitz, Jonathan E.
A1  - Rai, Kanti R.
A1  - Chiorazzi, Nicholas
A1  - Sherry, Barbara
T1  - Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance
JF  - Haematologica
N2  - Background The levels and clinical relevance of Th17 cells and other interleukin-17-producing cells have not been analyzed in chronic lymphocytic leukemia. The objective of this study was to quantify blood and tissue levels of Th17 and other interleukin-17-producing cells in patients with this disease and correlate blood levels with clinical outcome. 
Design and Methods: Intracellular interleukin-17A was assessed in blood and splenic mononuclear cells from patients with chronic lymphocytic leukemia and healthy subjects using flow cytometry. Interleukin-17A-producing cells were analyzed in formalin-fixed, paraffin-embedded spleen and lymph node sections using immunohistochemistry and immunofluorescence. 
Results: The absolute numbers of Th17 cells in peripheral blood mononuclear cells and the percentages of Th17 cells in spleen cell suspensions were higher in patients with chronic lymphocytic leukemia than in healthy subjects; in six out of eight paired chronic lymphocytic leukemia blood and spleen sample comparisons, Th17 cells were enriched in spleen suspensions. Circulating Th17 levels correlated with better prognostic markers and longer overall survival of the patients. Two "non-Th17" interleukin-17-expressing cells were identified in chronic lymphocytic leukemia spleens: proliferating cells of the granulocytic lineage and mature mast cells. Granulocytes and mast cells in normal spleens did not express interleukin-17. Conversely, both chronic lymphocytic leukemia and healthy lymph nodes contained similar numbers of interleukin-17+ mast cells as well as Th17 cells. 
Conclusions: Th17 cells are elevated in chronic lymphocytic leukemia patients with better prognostic markers and correlate with longer survival. Furthermore, non-Th17 interleukin-17A-expressing cells exist in chronic lymphocytic leukemia spleens as maturing granulocytes and mature mast cells, suggesting that the microenvironmental milieu in leukemic spleens promotes the recruitment and/or expansion of Th17 and other IL-17-expressing cells. The pathophysiology of Th17 and non-Th17-interleukin-producing cells in chronic lymphocytic leukemia and their distributions and roles in this disease merit further study.
KW  - disease
KW  - helper T cells
KW  - T(H)17 cells
KW  - tumor microenvironment
KW  - multiple myeloma
KW  - up regulation
KW  - mast cells
KW  - lineage
KW  - pathway
KW  - IL-17
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131290
VL  - 97
IS  - 4
ER  - 
TY  - JOUR
A1  - Zhao, Bo
A1  - Zhang, Keya
A1  - Bhuripanyo, Karan
A1  - Choi, Chan Hee J.
A1  - Villhauer, Eric B.
A1  - Li, Heng
A1  - Zheng, Ning
A1  - Kiyokawa, Hiroaki
A1  - Schindelin, Hermann
A1  - Yin, Jun
T1  - Profiling the Cross Reactivity of Ubiquitin with the Nedd8 Activating Enzyme by Phage Display
JF  - PLoS ONE
N2  - The C-terminal peptides of ubiquitin (UB) and UB-like proteins (UBLs) play a key role in their recognition by the specific activating enzymes (E1s) to launch their transfer through the respective enzymatic cascades thus modifying cellular proteins. UB and Nedd8, a UBL regulating the activity of cullin-RING UB ligases, only differ by one residue at their C-termini; yet each has its specific E1 for the activation reaction. It has been reported recently that UAE can cross react with Nedd8 to enable its passage through the UB transfer cascade for protein neddylation. To elucidate differences in UB recognition by UAE and NAE, we carried out phage selection of a UB library with randomized C-terminal sequences based on the catalytic formation of UB similar to NAE thioester conjugates. Our results confirmed the previous finding that residue 72 of UB plays a "gate-keeping" role in E1 selectivity. We also found that diverse sequences flanking residue 72 at the UB C-terminus can be accommodated by NAE for activation. Furthermore heptameric peptides derived from the C-terminal sequences of UB variants selected for NAE activation can function as mimics of Nedd8 to form thioester conjugates with NAE and the downstream E2 enzyme Ubc12 in the Nedd8 transfer cascade. Once the peptides are charged onto the cascade enzymes, the full-length Nedd8 protein is effectively blocked from passing through the cascade for the critical modification of cullin. We have thus identified a new class of inhibitors of protein neddylation based on the profiles of the UB C-terminal sequences recognized by NAE.
KW  - protein NEDD8
KW  - E1
KW  - system
KW  - conjugation
KW  - pathway
KW  - complex
KW  - ligases
KW  - purification
KW  - neddylation
KW  - expression
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128479
SN  - 1932-6203
VL  - 8
IS  - e70312
ER  - 
TY  - JOUR
A1  - Kato, Hiroki
A1  - Lu, Qiping
A1  - Rapaport, Doron
A1  - Kozjak-Pavlovic, Vera
T1  - Tom70 Is Essential for PINK1 Import into Mitochondria
JF  - PLoS ONE
N2  - PTEN induced kinase 1 (PINK1) is a serine/threonine kinase in the outer membrane of mitochondria (OMM), and known as a responsible gene of Parkinson's disease (PD). The precursor of PINK1 is synthesized in the cytosol and then imported into the mitochondria via the translocase of the OMM (TOM) complex. However, a large part of PINK1 import mechanism remains unclear. In this study, we examined using cell-free system the mechanism by which PINK1 is targeted to and assembled into mitochondria. Surprisingly, the main component of the import channel, Tom40 was not necessary for PINK1 import. Furthermore, we revealed that the import receptor Tom70 is essential for PINK1 import. In addition, we observed that although PINK1 has predicted mitochondrial targeting signal, it was not processed by the mitochondrial processing peptidase. Thus, our results suggest that PINK1 is imported into mitochondria by a unique pathway that is independent of the TOM core complex but crucially depends on the import receptor Tom70.
KW  - binding
KW  - outer-membrane proteins
KW  - Parkinsons diesease
KW  - intracellular membranes
KW  - quality control
KW  - pathway
KW  - recruitment
KW  - biogenesis
KW  - mechanisms
KW  - complex
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131061
VL  - 8
IS  - 3
ER  - 
TY  - JOUR
A1  - Tilstam, Pathricia V.
A1  - Gijbels, Marion J.
A1  - Habbeddine, Mohamed
A1  - Cudejko, Celine
A1  - Asare, Yaw
A1  - Theelen, Wendy
A1  - Zhou, Baixue
A1  - Döring, Yvonne
A1  - Drechsler, Maik
A1  - Pawig, Lukas
A1  - Simsekyilmaz, Sakine
A1  - Koenen, Rory R.
A1  - de Winther, Menno P. J.
A1  - Lawrence, Toby
A1  - Bernhagen, Jürgen
A1  - Zernecke, Alma
A1  - Weber, Christian
A1  - Noels, Heidi
T1  - Bone Marrow-Specific Knock-In of a Non-Activatable Ikkα Kinase Mutant Influences Haematopoiesis but Not Atherosclerosis in Apoe-Deficient Mice
JF  - PLOS ONE
N2  - Background: The Ikkα kinase, a subunit of the NF-kappa B-activating IKK complex, has emerged as an important regulator of inflammatory gene expression. However, the role of Ikkα-mediated phosphorylation in haematopoiesis and atherogenesis remains unexplored. In this study, we investigated the effect of a bone marrow (BM)-specific activation-resistant Ikk alpha mutant knock-in on haematopoiesis and atherosclerosis in mice. 
Methods and Results: Apolipoprotein E (Apoe)-deficient mice were transplanted with BM carrying an activation-resistant Ikkα gene (Ikkα(AA/AA) Apoe(-/-)) or with Ikkα(+/+) Apoe(-/-) BM as control and were fed a high-cholesterol diet for 8 or 13 weeks. Interestingly, haematopoietic profiling by flow cytometry revealed a significant decrease in B-cells, regulatory T-cells and effector memory T-cells in Ikkα(AA/AA) Apoe(-/-) BM-chimeras, whereas the naive T-cell population was increased. Surprisingly, no differences were observed in the size, stage or cellular composition of atherosclerotic lesions in the aorta and aortic root of Ikkα(AA/AA) Apoe(-/-) vs Ikkα(+/+) Apoe(-/-) BM-transplanted mice, as shown by histological and immunofluorescent stainings. Necrotic core sizes, apoptosis, and intracellular lipid deposits in aortic root lesions were unaltered. In vitro, BM-derived macrophages from Ikkα(AA/AA) Apoe(-/-) vs Ikkα(+/+) Apoe(-/-) mice did not show significant differences in the uptake of oxidized low-density lipoproteins (oxLDL), and, with the exception of Il-12, the secretion of inflammatory proteins in conditions of Tnf-α or oxLDL stimulation was not significantly altered. Furthermore, serum levels of inflammatory proteins as measured with a cytokine bead array were comparable. 
Conclusion: Our data reveal an important and previously unrecognized role of haematopoietic Ikkα kinase activation in the homeostasis of B-cells and regulatory T-cells. However, transplantation of Ikkα AA mutant BM did not affect atherosclerosis in Apoe(-/-) mice. This suggests that the diverse functions of Ikkα in haematopoietic cells may counterbalance each other or may not be strong enough to influence atherogenesis, and reveals that targeting haematopoietic Ikkα kinase activity alone does not represent a therapeutic approach.
KW  - NF-KAPPA-B
KW  - regulatory T cells
KW  - indoleamine 2,3-dioxygenase
KW  - dendritic cells
KW  - gene expression
KW  - increases atherosclersosis
KW  - receptor
KW  - inhibition
KW  - pathway
KW  - beta
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117450
VL  - 9
IS  - 2
ER  - 
TY  - JOUR
A1  - Hausmann, Stefan
A1  - Brandt, Evelyn
A1  - Köchel, Carolin
A1  - Einsele, Hermann
A1  - Bargou, Ralf C.
A1  - Seggewiss-Bernhardt, Ruth
A1  - Stühmer, Thorsten
T1  - Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines
JF  - PLoS ONE
N2  - Multiple myeloma (MM) is a generally fatal plasma cell cancer that often shows activation of the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway. Targeted pharmacologic therapies, however, have not yet progressed beyond the clinical trial stage, and given the complexity of the PI3K/Akt signalling system (e.g. multiple protein isoforms, diverse feedback regulation mechanisms, strong variability between patients) it is mandatory to characterise its ramifications in order to better guide informed decisions about the best therapeutic approaches. Here we explore whether serum and glucocorticoid-regulated kinase 3 (SGK3), a potential downstream effector of PI3K, plays a role in oncogenic signalling in MM cells-either in concert with or independent of Akt. SGK3 was expressed in all MM cell lines and in all primary MM samples tested. Four MM cell lines representing a broad range of intrinsic Akt activation (very strong: MM. 1s, moderate: L 363 and JJN-3, absent: AMO-1) were chosen to test the effects of transient SGK3 knockdown alone and in combination with pharmacological inhibition of Akt, PI3K-p110\(\alpha\), or in the context of serum starvation. Although the electroporation protocol led to strong SGK3 depletion for at least 5 days its absence had no substantial effect on the activation status of potential downstream substrates, or on the survival, viability or proliferation of MM cells in all experimental contexts tested. We conclude that it is unlikely that SGK3 plays a significant role for oncogenic signalling in multiple myeloma.
KW  - Akt
KW  - phosphorylation
KW  - downstream
KW  - mechanism
KW  - pathway
KW  - isoforms
KW  - activation
KW  - cancer
KW  - inhibition
KW  - phosphatidylinositol 3-kinase/Akt
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148708
VL  - 10
IS  - 4
ER  - 
TY  - JOUR
A1  - Rickman, Kimberly A.
A1  - Lach, Francis P.
A1  - Abhyankar, Avinash
A1  - Donovan, Frank X.
A1  - Sanborn, Erica M.
A1  - Kennedy, Jennifer A.
A1  - Sougnez, Carrie
A1  - Gabriel, Stacey B.
A1  - Elemento, Olivier
A1  - Chandrasekharappa, Settara C.
A1  - Schindler, Detlev
A1  - Auerbach, Arleen D.
A1  - Smogorzewska, Agata
T1  - Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia
JF  - Cell Reports
N2  - Fanconi anemia (FA) is a rare bone marrow failure and cancer predisposition syndrome resulting from pathogenic mutations in genes encoding proteins participating in the repair of DNA interstrand crosslinks (ICLs). Mutations in 17 genes (FANCA-FANCS) have been identified in FA patients, defining 17 complementation groups. Here, we describe an individual presenting with typical FA features who is deficient for the ubiquitin-conjugating enzyme (E2), UBE2T. UBE2T is known to interact with FANCL, the E3 ubiquitin-ligase component of the multiprotein FA core complex, and is necessary for the monoubiquitination of FANCD2 and FANCI. Proband fibroblasts do not display FANCD2 and FANCI monoubiquitination, do not form FANCD2 foci following treatment with mitomycin C, and are hypersensitive to crosslinking agents. These cellular defects are complemented by expression of wild-type UBE2T, demonstrating that deficiency of the protein UBE2T can lead to Fanconi anemia. UBE2T gene gains an alias of FANCT.
KW  - cross-link repair
KW  - DNA repair
KW  - gene
KW  - mutations
KW  - aldehydes
KW  - somatic mosaicism
KW  - pathway
KW  - monoubiquitination
KW  - diagnosis
KW  - proteins
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-151525
VL  - 12
SP  - 35
EP  - 41
ER  -